Article
Biochemistry & Molecular Biology
Sajjad Ahmad, Taghreed N. Almanaa, Saifullah Khan, Salma Mohammed Aljahdali, Yasir Waheed, Mohammad Abdullah Aljasir, Wafa Abdullah I. Al-Megrin, Aamir Aziz, Muhammad Ateeq, Fazli Amin, Saeed Ullah Khattak, Samira Sanami
Summary: This study used computer-aided drug discovery methods to identify three promising compounds as potential therapeutic targets for FGFR3 in bladder cancer. Molecular dynamics simulations and energy analysis confirmed the binding stability of these compounds with FGFR3.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
(2023)
Article
Oncology
Christian Kollmannsberger, Carolyn D. Britten, Anthony J. Olszanski, Joan Andrews Walker, Wei Zang, Melinda D. Willard, David B. Radtke, Daphne L. Farrington, Katherine M. Bell-McGuinn, Amita Patnaik
Summary: The study demonstrated acceptable safety and tolerability of LY3076226 up to the 5.0 mg/kg dose, with no dose-limiting toxicities reported. Although no responses were seen with LY3076226 treatment, stable disease persisting for > 6 months was observed in one patient receiving 3.2 mg/kg of LY3076226.
INVESTIGATIONAL NEW DRUGS
(2021)
Article
Medicine, General & Internal
Hongqi Zhang, Gang Xiang, Jiong Li, Sihan He, Yunjia Wang, Ang Deng, Yuxiang Wang, Chaofeng Guo, Xiuyuan Hao
Summary: This study investigated the relationship between congenital scoliosis (CS) and fibroblast growth factor 23 (FGF23). The results showed that CS patients had increased FGF23 mRNA levels in the peripheral blood and decreased bone mineral density. Additionally, FGF23 may contribute to osteopenia in CS patients through the FGFr3/TNAP/OPN pathway.
CHINESE MEDICAL JOURNAL
(2023)
Article
Medicine, General & Internal
Hongqi Zhang, Gang Xiang, Jiong Li, Sihan He, Yunjia Wang, Ang Deng, Yuxiang Wang, Chaofeng Guo
Summary: The study investigates the relationship between congenital scoliosis (CS) and fibroblast growth factor 23 (FGF23). The results show that CS patients have increased peripheral blood FGF23 mRNA levels and decreased bone mineral density, suggesting that FGF23 may contribute to osteopenia in CS patients through the FGFr3/TNAP/OPN pathway.
CHINESE MEDICAL JOURNAL
(2023)
Article
Biochemical Research Methods
Xianghua Xiong, Yujin Qiu, Jiahao Zheng, Ling Zhou, Qingyang Wang, Jinglun Pang, Weicai Zhang, Huipeng Chen, Gang Liu, Xiaodong Han
Summary: A specific monoclonal antibody ML419 has been found to disrupt the recognition between Botulinum neurotoxin serotype A (BoNT/A) and FGFR3, effectively preventing BoNT/A from entering neurons. In vivo experiments show that ML419 has a strong protective effect, making it a promising candidate for the development of therapeutics against BoNT/A.
PROTEIN EXPRESSION AND PURIFICATION
(2024)
Article
Immunology
Basudev Paudyal, Adam McNee, Pramila Rijal, B. Veronica Carr, Alejandro Nunez, John McCauley, Rodney S. Daniels, Alain R. Townsend, John A. Hammond, Elma Tchilian
Summary: Prophylactic intravenous administration of specific monoclonal antibodies in pigs showed significant reduction in lung pathology and virus loads, but not consistent reduction in nasal shedding. The effect on lung pathology and virus load is consistent across different doses, suggesting that lower doses may be effective in reducing disease severity.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Immunology
Mehdi Mohammadi, Mahmood Jeddi-Tehrani, Forough Golsaz-Shirazi, Mohammad Arjmand, Tannaz Bahadori, Mohammad Ali Judaki, Fariba Shiravi, Hengameh Ahmadi Zare, Farzaneh Notash Haghighat, Maryam Mobini, Mohammad Mehdi Amiri, Fazel Shokri
Summary: Overexpression of HER2 is common in many types of cancer, and the novel bispecific anti-HER2 antibody trasintuzumab, which combines trastuzumab and hersintuzumab, shows promising anti-tumor activity in preclinical studies, suggesting its potential as a therapeutic candidate for HER2-overexpressing cancers.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Vishnu Mohan, Jean P. Gaffney, Inna Solomonov, Maxim Levin, Mordehay Klepfish, Sophia Akbareian, Barbara Grunwald, Orly Dym, Miriam Eisenstein, Kenneth H. Yu, David P. Kelsen, Achim Kruger, Dylan R. Edwards, Irit Sagi
Summary: The study successfully developed a monoclonal antibody GSM-192 targeting matrix metalloproteinase 7, which induced pancreatic cancer cell apoptosis, reduced migration, and increased sensitivity to chemotherapy.
Review
Oncology
Claudia Maria Ascione, Fabiana Napolitano, Daniela Esposito, Alberto Servetto, Stefania Belli, Antonio Santaniello, Sarah Scagliarini, Felice Crocetto, Roberto Bianco, Luigi Formisano
Summary: Bladder cancer is a heterogeneous malignancy and FGFR3 genomic alterations have emerged as potent oncogenic drivers. In this review, the role of FGFR3 in bladder cancer and the state-of-art of anti-FGFR3 treatment are summarized. Additionally, the clinical and molecular features of FGFR3-altered bladder cancers are investigated.
CANCER TREATMENT REVIEWS
(2023)
Article
Biochemistry & Molecular Biology
Jinfang Cui, Yuchao He, Fuyi Zhu, Wenchen Gong, Ran Zuo, Yu Wang, Yi Luo, Liwei Chen, Chengmeng Wang, Gengwei Huo, Hailing Lu, Zhiyong Liu, Peng Chen, Hua Guo
Summary: The combination of anti-HER2 monoclonal antibody inetetamab and cisplatin has synergistic effects in LUAD cells, inducing pyroptosis and enhancing antitumor efficacy. Mechanistically, this combination therapy inhibits HER2/AKT/Nrf2 signaling, increases ROS levels, and triggers NLRP3/caspase-1/GSDMB-mediated pyroptosis. Additionally, cisplatin enhances the PBMC-killing ability of inetetamab by inducing GSDMB-mediated pyroptosis, possibly through increased IFN-gamma secretion.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2023)
Article
Biochemistry & Molecular Biology
Xuexiang Li, Yunxue Li, Bing Liu, Liang Chen, Fang Lyu, Pu Zhang, Qingliu He, Lulin Cheng, Chunyu Liu, Yarong Song, Yifei Xing
Summary: In this study, it was found that Erdafitinib induces incomplete autophagy and increases intracellular reactive oxygen species levels to kill cells. A resistant cell line, RT-112-RS, was established and P4HA2 was identified as a key player in Erdafitinib resistance. Further investigation revealed that P4HA2 stabilizes HIF-1a protein and activates downstream target genes to reduce reactive oxygen species levels in bladder cancer. These findings highlight the significant role of P4HA2 in mediating acquired resistance to Erdafitinib and suggest it as a potential target for bladder cancer treatment.
Article
Oncology
Guodong Chen, Peizhong Kong, Miaomiao Yang, Wanglai Hu, Kevin M. Prise, K. N. Yu, Shujun Cui, Feng Qin, Gang Meng, Waleed Abdelbagi Almahi, Lili Nie, Wei Han
Summary: GOLPH3 mediates radioresistance in lung adenocarcinoma (LUAD) by stabilizing EGFR, and targeted suppression of GOLPH3 could enhance the sensitivity of LUAD to radiation therapy.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2022)
Article
Biochemistry & Molecular Biology
Igor E. Eliseev, Valeria M. Ukrainskaya, Anna N. Yudenko, Anna D. Mikushina, Stanislav Shmakov, Anastasiya Afremova, Viktoria M. Ekimova, Anna A. Vronskaia, Nickolay A. Knyazev, Olga Shamova
Summary: The novel heavy-chain antibodies developed in this study target the ErbB3 receptor through a unique approach, showing promising potential in overcoming resistance to pharmacological inhibition of EGFR and HER2 receptors in cancer treatment. These antibodies exhibit non-competitive binding to distinct epitopes on the receptor and have demonstrated efficacy in inhibiting proliferation through different mechanisms, paving the way for potential development of new therapeutic strategies for malignant tumors.
Editorial Material
Oncology
Wolfgang A. Weber, Zohreh Varasteh, Katja Fritschle, Volker Morath
Summary: FAP-targeted therapies have shown limited success so far, but FAP imaging offers new opportunities for patient selection and monitoring tumor response.
CLINICAL CANCER RESEARCH
(2022)
Article
Veterinary Sciences
Shuo Xu, Jingshu Xie, Shuaiyu Wang, Na Tang, Junli Feng, Youhong Su, Gebin Li
Summary: Monoclonal antibodies targeting PD-1 have shown promising results in treating human cancers and have also been effective in clinical trials for canine cancers. This case report highlights the successful response to PD-1 blockade treatment in a canine adenocarcinoma patient, with partial remission lasting for 6 months. This is the first report of such response in canine adenocarcinoma.
FRONTIERS IN VETERINARY SCIENCE
(2023)
Review
Anatomy & Morphology
Lu M. Yang, David M. Ornitz
DEVELOPMENTAL DYNAMICS
(2019)
Article
Anatomy & Morphology
Andrew S. Hagan, Michael Boylan, Craig Smith, Estela Perez-Santamarina, Karolina Kowalska, Irene H. Hung, Renate M. Lewis, Mohammad K. Hajihosseini, Mark Lewandoski, David M. Ornitz
DEVELOPMENTAL DYNAMICS
(2019)
Article
Developmental Biology
Andrew S. Hagan, Bo Zhang, David M. Ornitz
Article
Biochemistry & Molecular Biology
Yongjun Yin, David M. Ornitz
Article
Developmental Biology
Emily M. A. Lewis, Savita Sankar, Caili Tong, Ethan S. Patterson, Laura E. Waller, Paul Gontarz, Bo Zhang, David M. Ornitz, Kristen L. Kroll
DEVELOPMENTAL BIOLOGY
(2020)
Article
Anatomy & Morphology
Lu M. Yang, Lisa Stout, Michael Rauchman, David M. Ornitz
DEVELOPMENTAL DYNAMICS
(2020)
Article
Anatomy & Morphology
Yutao Su, Lu M. Yang, David M. Ornitz
Summary: The study indicates that both MAPK and PI3K pathways are crucial downstream mediators of FGF20-FGFR1 signaling in cochlear hair cell and supporting cell differentiation.
DEVELOPMENTAL DYNAMICS
(2021)
Article
Anatomy & Morphology
Connor C. Leek, Jaclyn M. Soulas, Iman Bhattacharya, Elahe Ganji, Ryan C. Locke, Megan C. Smith, Jaysheel D. Bhavsar, Shawn W. Polson, David M. Ornitz, Megan L. Killian
Summary: This study investigated the role of Fgf9 in regulating the size of the deltoid tuberosity, revealing that Fgf9 deficiency affected cartilage growth and mineralization, as well as transcriptional profiles of skeletal muscle. The findings suggest that Fgf9 may play a crucial role in muscle-bone cross-talk during both embryonic and postnatal development.
DEVELOPMENTAL DYNAMICS
(2021)
Article
Cell Biology
Jessica Weant, David D. Eveleth, Amuthakannan Subramaniam, Jennifer Jenkins-Eveleth, Michael Blaber, Ling Li, David M. Ornitz, Asaf Alimardanov, Trevor Broadt, Hui Dong, Vinay Vyas, Xiaoyi Yang, Ralph A. Bradshaw
Summary: The two human FGF1 derivatives showed promising results in stimulating rabbit corneal endothelial cell proliferation, indicating their potential for regenerating corneal endothelial deficits in humans.
Article
Biochemistry & Molecular Biology
Elahe Ganji, Connor Leek, William Duncan, Debabrata Patra, David M. Ornitz, Megan L. Killian
Summary: This study investigates the role of Fgf9 in the development and function of the postnatal enthesis. By conditional knockout of Fgf9 in mouse tendons and entheses, the researchers found that Fgf9 is important for the structural and functional development of the enthesis. Mice with Fgf9 knockout showed thinner tendons, reduced bone mineralization, increased cellularity, and decreased mechanical properties in the entheses.
Article
Cardiac & Cardiovascular Systems
Dzmitry Matsiukevich, Attila Kovacs, Tiandao Li, Kristen Kokkonen-Simon, Scot J. Matkovich, Sunday S. Oladipupo, David M. Ornitz
Summary: Heart failure (HF) is a common and serious condition, particularly in older adults and patients with multiple metabolic comorbidities. Heart failure with preserved ejection fraction (HFpEF) is a clinical syndrome characterized by organ dysfunction and symptoms of heart failure, despite a normal or near-normal left ventricular ejection fraction. In this study, researchers successfully created a rodent model with a robust HFpEF phenotype, exhibiting characteristics and manifestations similar to the human disease.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
(2023)
Article
Anatomy & Morphology
Kendra K. Wernle, Michael A. Sonnenfelt, Connor C. Leek, Elahe Ganji, Anna Lia Sullivan, Claudia Offutt, Jordan Shuff, David M. Ornitz, Megan L. Killian
Summary: The study reveals that FGFR signaling plays a critical role in regulating the growth and maintenance of tendon/ligament attachments and the size and shape of bony eminences.
DEVELOPMENTAL DYNAMICS
(2023)
Review
Medicine, Research & Experimental
David M. Ornitz, Nobuyuki Itoh
Summary: This review provides an overview of the fibroblast growth factor (FGF) family and focuses on new developments in the field since 2015. Highlights of the past 6 years include advancements in experimental modulation of FGF signaling, clinical use of small molecule FGFR inhibitors, expanded understanding of endocrine FGF signaling, and the roles of FGF signaling in stem cells, tissue homeostasis, regeneration, and neuropsychiatric diseases.
WIRES MECHANISMS OF DISEASE
(2022)
Article
Medicine, Research & Experimental
Kel Vin Woo, Isabel Y. Shen, Carla J. Weinheimer, Attila Kovacs, Jessica Nigro, Chieh-Yu Lin, Murali Chakinala, Derek E. Byers, David M. Ornitz
Summary: Research suggests that activation of endothelial FGFR signaling could be therapeutic for hypoxia-induced pulmonary hypertension by inhibiting the TGF-beta pathway-mediated EndMT process.
JOURNAL OF CLINICAL INVESTIGATION
(2021)
Article
Endocrinology & Metabolism
Stephen Stone, Daniel J. Wegner, Jennifer A. Wambach, F. Sessions Cole, Fumihiko Urano, David M. Ornitz
JOURNAL OF THE ENDOCRINE SOCIETY
(2020)